EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Theranostics for Triple-Negative Breast Cancer

Hyeryeon Choi iD, Kwangsoon Kim iD

Diagnostics · 11.01.2023 · 13 (2) · 272

DOI: 10.3390/diagnostics13020272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 11.01.2023. Verfasst von Hyeryeon Choi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Republic of Korea. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.

Schlagwörter

Stichwörter der Autor:innen

breast cancerimmunotherapynanomedicinetheranostics

Autor:innen und Institutionen

  • Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Republic of Korea.
  • Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

ORCID-Profile: Hyeryeon Choi, Kwangsoon Kim

Zitieren

APA

Choi, H., & Kim, K. (2023). Theranostics for Triple-Negative Breast Cancer. Diagnostics, 13(2), 272. https://doi.org/10.3390/diagnostics13020272

Vancouver

Choi H, Kim K. Theranostics for Triple-Negative Breast Cancer. Diagnostics. 2023;13(2):272. doi:10.3390/diagnostics13020272

BibTeX
@article{Choi2023,
  author = {Choi, Hyeryeon and Kim, Kwangsoon},
  title = {Theranostics for Triple-Negative Breast Cancer},
  journal = {Diagnostics},
  year = {2023},
  volume = {13},
  number = {2},
  pages = {272},
  doi = {10.3390/diagnostics13020272}
}
Kostenlos starten →